SG11202006712XA - Treatment of ophthalmologic diseases - Google Patents

Treatment of ophthalmologic diseases

Info

Publication number
SG11202006712XA
SG11202006712XA SG11202006712XA SG11202006712XA SG11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA
Authority
SG
Singapore
Prior art keywords
treatment
ophthalmologic diseases
ophthalmologic
diseases
Prior art date
Application number
SG11202006712XA
Other languages
English (en)
Inventor
Aaron Osborne
Jayashree Sahni
Robert James Weikert
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of SG11202006712XA publication Critical patent/SG11202006712XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202006712XA 2018-02-06 2019-02-05 Treatment of ophthalmologic diseases SG11202006712XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862627103P 2018-02-06 2018-02-06
US201862729333P 2018-09-10 2018-09-10
PCT/EP2019/052704 WO2019154776A1 (en) 2018-02-06 2019-02-05 Treatment of ophthalmologic diseases

Publications (1)

Publication Number Publication Date
SG11202006712XA true SG11202006712XA (en) 2020-08-28

Family

ID=65352014

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006712XA SG11202006712XA (en) 2018-02-06 2019-02-05 Treatment of ophthalmologic diseases

Country Status (12)

Country Link
US (2) US20210139576A1 (he)
EP (1) EP3749359A1 (he)
JP (3) JP7005772B2 (he)
KR (1) KR20200119274A (he)
CN (1) CN111699004A (he)
AU (1) AU2019219004A1 (he)
CA (1) CA3088355A1 (he)
IL (1) IL276383B2 (he)
MX (1) MX2020007527A (he)
SG (1) SG11202006712XA (he)
TW (1) TWI831764B (he)
WO (1) WO2019154776A1 (he)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
CN116059318A (zh) 2018-01-26 2023-05-05 加利福尼亚大学董事会 用于使用抗vegf剂治疗血管生成病症的方法和组合物
AU2020326243A1 (en) * 2019-08-06 2022-02-17 F. Hoffmann-La Roche Ag Personalized treatment of ophthalmologic diseases
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20220104756A (ko) 2019-11-25 2022-07-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구내 신생혈관형성을 위한 장기지속형 vegf 억제제
IL300616A (he) 2020-09-04 2023-04-01 Hoffmann La Roche נוגדן הנקשר ל-vegf-a ו-ang2 ושיטות שימוש
CN116234574A (zh) * 2020-09-17 2023-06-06 江苏恒瑞医药股份有限公司 特异性结合vegf和ang-2的双特异性抗原结合分子
JP2024512701A (ja) * 2021-03-30 2024-03-19 アブプロ コーポレーション 抗ang2×vegf多重特異性抗体を用いて脈絡膜新生血管形成を治療するための方法
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1325932B9 (en) 1997-04-07 2006-07-19 Genentech, Inc. Anti-vegf antibodies
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2519543T (pt) 2009-12-29 2016-10-07 Emergent Product Dev Seattle Proteínas de ligação de heterodímero e suas utilizações
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
EP4360709A3 (en) * 2011-01-13 2024-07-03 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
EP2794905B1 (en) 2011-12-20 2020-04-01 MedImmune, LLC Modified polypeptides for bispecific antibody scaffolds
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
HUE056217T2 (hu) * 2012-07-13 2022-02-28 Roche Glycart Ag Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
KR102177437B1 (ko) * 2012-08-21 2020-11-12 옵코 파마슈티칼스, 엘엘씨 리포좀 제제
EP2992010B1 (en) * 2013-04-29 2021-03-24 F.Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
KR20150063728A (ko) 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-C/항 Ang2 이중 특이 항체
TWI761959B (zh) * 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CA2970315C (en) * 2014-12-11 2023-08-22 Bayer Healthcare Llc Use of anti-vegf agents to treat lesions in macular degeneration patients
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
US10654922B2 (en) * 2016-05-13 2020-05-19 Askgene Pharma Inc. Angiopoietin 2, VEGF dual antagonists

Also Published As

Publication number Publication date
AU2019219004A1 (en) 2020-07-16
JP2022046738A (ja) 2022-03-23
JP2023099094A (ja) 2023-07-11
KR20200119274A (ko) 2020-10-19
TWI831764B (zh) 2024-02-11
IL276383B1 (he) 2023-09-01
MX2020007527A (es) 2020-09-09
IL276383A (he) 2020-09-30
CN111699004A (zh) 2020-09-22
IL276383B2 (he) 2024-01-01
JP2021506947A (ja) 2021-02-22
TW202000700A (zh) 2020-01-01
EP3749359A1 (en) 2020-12-16
US20210139576A1 (en) 2021-05-13
WO2019154776A1 (en) 2019-08-15
JP7005772B2 (ja) 2022-02-10
CA3088355A1 (en) 2019-08-15
US20230416353A1 (en) 2023-12-28
JP7273204B2 (ja) 2023-05-12

Similar Documents

Publication Publication Date Title
IL276383B1 (he) טיפול במחלות אופתאלמולוגיות
SG11202006374VA (en) Treatment of demyelinating diseases
IL268357A (he) תאים פוטורצפטורים לטיפול במחלות הרישתית
ZA201903003B (en) Treatment of neurological diseases
IL289405A (he) טיפול מותאם אישית במחלות עיניים
IL282643A (he) שילובי רפוי לטיפול במחלות המטולוגיות
SG11202010585WA (en) New treatment of interstitial lung diseases
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
IL269698B (he) שיטות למניעה או טיפול במחלות עיניים
GB202015959D0 (en) Treatment of diseases involving NAD
SG11202001595SA (en) Angio-3 for treatment of retinal angiogenic diseases
GB201805100D0 (en) Treatment of sarcopenic diseases
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
IL259381B (he) מיראבגרון לטיפול במחלות רשתית
IL282360A (he) טיפול למחלות נוירולוגיות
IL282898A (he) תרכובות אופטלמיות ושיטות לטיפול במחלות עור ומחלות עיניים
GB201914516D0 (en) Treatment of eye disease
SG11202010034WA (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY
GB201909438D0 (en) Treatment of diseases
GB201604359D0 (en) Treatment of tissue disorders
GB201805556D0 (en) Treatment of ophthalmological conditions
GB201904764D0 (en) Treatment of ophthalmological conditions
GB201811912D0 (en) Treatment of disease
GB201811911D0 (en) Treatment of disease
GB201810974D0 (en) Treatment of disease